Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
Rhea-AI Summary
Revelation Biosciences (NASDAQ:REVB) announced the initiation of GMP manufacturing for GEMINI and matching placebo to supply later‑stage clinical studies. The manufacturing run will provide clinical drug supply needed to support randomized, double‑blind, placebo‑controlled trials and is described as a critical step toward advancing GEMINI's development and approval pathway.
The company said it is working with a leading global contract manufacturing organization and noted it met with the FDA in December 2025 to seek agency feedback on the clinical development and regulatory pathway for GEMINI as a treatment for acute kidney injury (AKI); Revelation is awaiting the FDA meeting minutes.
Positive
- GMP manufacturing for GEMINI and placebo initiated
- Manufacture will provide clinical supply for later‑stage studies
- Enables randomized double‑blind, placebo‑controlled trials
- Engaged a "leading global" contract manufacturing organization
- Met with FDA in December 2025 to discuss regulatory pathway
Negative
- Official FDA meeting minutes pending, creating regulatory timing uncertainty
News Market Reaction – REVB
On the day this news was published, REVB declined 1.08%, reflecting a mild negative market reaction. Argus tracked a peak move of +16.8% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $60K from the company's valuation, bringing the market cap to $5M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
REVB gained 9.68% while momentum-flagged peers ELAB and DRMA fell about 5–6%. Broader biotech showed pressure, but REVB’s move diverged positively.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Special meeting quorum | Neutral | +0.1% | Confirmed quorum and reiterated regulatory and financial progress, slight price uptick. |
| Nov 20 | Clinical/FDA update | Positive | -0.5% | End-of-phase 1 package accepted and positive PRIME data, but shares slipped modestly. |
| Nov 06 | Earnings and cash update | Negative | -2.9% | Q3 loss, going concern language, and financing reliance drove a multi‑percent decline. |
| Oct 29 | Meeting cancellation | Negative | -4.5% | Technical issues forced canceling a special meeting, prompting a sharper share pullback. |
| Oct 15 | Meeting adjournment | Negative | -2.2% | Adjourned special meeting for lack of votes, adding governance overhang and losses. |
Clinical milestones for Gemini have often seen mixed or even negative next-day moves, while governance and meeting logistics skew slightly negative in price reaction.
Over the last few months, Revelation has focused on both clinical and corporate milestones. In Q3 2025, it reported financials with a going concern warning but highlighted PRIME data and cash of $12.7M. Through late 2025, it managed multiple special meetings tied to warrant inducements and share approvals. Clinically, the FDA accepted its end-of-phase 1 package for Gemini in November 2025. Today’s GMP manufacturing update builds on that pathway toward later-stage trials in AKI.
Regulatory & Risk Context
An amended Form S-3/A registers shares underlying Class I warrants at $2.20 per share. If fully exercised for cash, Revelation could receive up to $28,743,000. The company is not selling shares directly in this prospectus, and the shelf had not yet become effective with no recorded usage.
Market Pulse Summary
This announcement advances Gemini by initiating GMP manufacturing of active drug and placebo, enabling randomized, double-blind, placebo-controlled studies in acute kidney injury. It follows earlier PRIME Phase 1b data and an FDA end-of-phase 1 interaction, marking a shift toward later-stage development. Investors may track upcoming trial designs, FDA meeting minutes from December 2025, and any use of the warrant-related S-3/A capacity as key future catalysts and risks.
Key Terms
gmp manufacturing technical
placebo-controlled medical
double blinded medical
acute kidney injury medical
fda regulatory
AI-generated analysis. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP manufacturing of GEMINI and placebo. This manufacturing run will provide the Company with clinical drug supply for later stage clinical studies.
"We are delighted to be working with a leading global contract manufacturing organization," said James Rolke, Chief Executive Officer of Revelation. "The manufacture of additional drug supply and placebo will fulfill a critical step in advancing Revelation's pipeline and accelerating timelines for upcoming clinical programs."
The manufacture of drug and Placebo enables the company to conduct randomized double blinded, placebo-controlled clinical studies, and is an integral part of the broader strategy to move Gemini toward approval.
Revelation met with FDA in December 2025 and is currently awaiting the official meeting minutes. The primary purpose of this meeting was to establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI).
About Gemini
Gemini is the Company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation. Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEMINI-AKI program). Gemini is also being developed as a treatment for chronic kidney disease (GEMINI-CKD program), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI) and as a treatment to prevent post-surgical infection (GEMINI-PSI program). The potential of Gemini has been demonstrated in multiple preclinical models of AKI, CKD and infection, as well as in two phase 1 clinical studies. See additional detail here.
About AKI
Acute Kidney Injury or AKI, also known as acute renal failure, is defined as a rapid loss of kidney function. AKI causes a build-up of waste products in blood and makes it more difficult for kidneys to maintain the correct balance of fluid in the body. AKI can also significantly impact other organs such as the brain, heart, and lungs. Severe AKI requiring dialysis significantly increases the likelihood of worse outcomes including longer time in an ICU, potential to develop chronic kidney disease and death.
AKI is a major cause of morbidity and mortality, affecting more than
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of chronic kidney disease, prevention for post-surgical infection and as a treatment for acute kidney injury.
For more information on Revelation, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Company Contact
Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Revelation Biosciences (REVB) announce on January 7, 2026 about GEMINI?
How does the GEMINI GMP run affect REVB's clinical plans?
Did REVB meet with the FDA about GEMINI and when?
Is Revelation working with an external manufacturer for GEMINI (REVB)?
Are the FDA meeting minutes for REVB's December 2025 meeting available?
